The role of the tissue factor and its inhibitor in the development of subclinical atherosclerosis in people living with HIV
- PMID: 28749986
- PMCID: PMC5531520
- DOI: 10.1371/journal.pone.0181533
The role of the tissue factor and its inhibitor in the development of subclinical atherosclerosis in people living with HIV
Abstract
Introduction: HIV infection is associated with an increased risk of cardiovascular disease in connection with atherosclerosis and thromboembolic complications. The pathogenesis of atherosclerosis is still unclear in this group of patients. Studies on pathogenesis of atherosclerosis in the general population emphasize the role of the extrinsic pathway of blood coagulation, particularly the tissue factor (TF) and tissue factor pathway inhibitor (TFPI). The effect of persistent activation of the immune system on enhanced expression of TF on the surface of monocytes in subjects infected with HIV is known to be correlated with the level of HIV RNA in blood serum.
Study aim: The aim of this study was to evaluate the concentration of TF and its inhibitor TFPI in blood plasma, the impact of traditional and non-traditional cardiovascular risk factors on their concentration and the impact of both markers of haemostasis on the severity of subclinical atherosclerosis as assessed by the intima-media measurement of the carotid artery in HIV infected patients.
Materials: The study included 121 HIV-infected people with known clinical, immunological and virological status. The control group consisted of 42 healthy individuals, selected in terms of age and sex.
Results and conclusions: Higher concentrations of TF occurred in HIV-infected patients with a low current plasma HIV RNA level, nadir CD4+ T-cell count and longer duration of cumulative antiretroviral treatment. In multivariate analysis, it was the length of cumulative NRTI treatment that impacted on the concentration of TF. The determinants of cardiovascular disease (CVD) risk factors and inflammatory markers did not show any effect on the concentrations of TF. The TFPI level in HIV-infected patients was significantly higher than in the control group and was negatively correlated with the current level of HIV RNA and nadir CD4+ T-cell count, being higher in patients subjected to antiretroviral treatment. It was shown that the higher the cardiovascular risk and the higher the levels of total cholesterol, low-density lipoprotein cholesterol (LDL) and non-high-density lipoprotein cholesterol (non-HDL), the higher the concentrations of TFPI observed. The levels of TF and TFPI were positively correlated with carotid intima media thickness (cIMT); in the multivariate analysis, TF, non-HDL cholesterol and lifetime smoking (pack-years) independently affected the growth of cIMT. A similar effect on cIMT was demonstrated by TFPI.
Conflict of interest statement
Figures



Similar articles
-
Association of Lower Adiponectin Plasma Levels, Increased Age and Smoking with Subclinical Atherosclerosis in Patients with HIV-1 Infection.Curr HIV Res. 2020;18(4):292-306. doi: 10.2174/1570162X18666200609114741. Curr HIV Res. 2020. PMID: 32516102
-
Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.Int Angiol. 2008 Aug;27(4):296-301. Int Angiol. 2008. PMID: 18677291
-
Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.PLoS One. 2015 Apr 27;10(4):e0117125. doi: 10.1371/journal.pone.0117125. eCollection 2015. PLoS One. 2015. PMID: 25915208 Free PMC article.
-
Interdependent biological systems, multi-functional molecules: the evolving role of tissue factor pathway inhibitor beyond anti-coagulation.Thromb Res. 2010 Apr;125 Suppl 1(Suppl 1):S57-9. doi: 10.1016/j.thromres.2010.01.039. Epub 2010 Feb 24. Thromb Res. 2010. PMID: 20185167 Free PMC article. Review.
-
Mouse Models of HIV-Associated Atherosclerosis.Int J Mol Sci. 2025 Apr 5;26(7):3417. doi: 10.3390/ijms26073417. Int J Mol Sci. 2025. PMID: 40244289 Free PMC article. Review.
Cited by
-
Contribution of Behavioral Health Factors to Non-AIDS-Related Comorbidities: an Updated Review.Curr HIV/AIDS Rep. 2020 Aug;17(4):354-372. doi: 10.1007/s11904-020-00498-y. Curr HIV/AIDS Rep. 2020. PMID: 32314325 Free PMC article. Review.
-
Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach.J Infect Dis. 2020 Aug 17;222(6):929-939. doi: 10.1093/infdis/jiaa196. J Infect Dis. 2020. PMID: 32310273 Free PMC article. Clinical Trial.
-
Evidence for Persistent Monocyte and Immune Dysregulation After Prolonged Viral Suppression Despite Normalization of Monocyte Subsets, sCD14 and sCD163 in HIV-Infected Individuals.Pathog Immun. 2019 Dec 17;4(2):324-362. doi: 10.20411/pai.v4i2.336. eCollection 2019. Pathog Immun. 2019. PMID: 31893252 Free PMC article.
-
Elevated Microparticle Tissue Factor Activity Is Associated With Carotid Artery Plaque in HIV-Infected Women.J Acquir Immune Defic Syndr. 2019 May 1;81(1):36-43. doi: 10.1097/QAI.0000000000001988. J Acquir Immune Defic Syndr. 2019. PMID: 30789451 Free PMC article.
-
Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings.Curr Opin HIV AIDS. 2018 May;13(3):187-195. doi: 10.1097/COH.0000000000000458. Curr Opin HIV AIDS. 2018. PMID: 29432231 Free PMC article. Review.
References
-
- Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013;39(4):633–645. doi: 10.1016/j.immuni.2013.10.001 - DOI - PMC - PubMed
-
- Funderburg NT, Mayne E, Sieg SF, Asaad R, Jiang W, Kalinowska M, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood. 2010;115:161–167. doi: 10.1182/blood-2009-03-210179 - DOI - PMC - PubMed
-
- Steffel J, Lűscher TF, Tanner FC. Tissue Factor in Cardiovascular Disease: Molecular Mechanisms and Clinical Implifications. Circulation. 2006;113: 722–731. doi: 10.1161/CIRCULATIONAHA.105.567297 - DOI - PubMed
-
- Kotschy M, Kotschy D, Witkiewicz W: The role of tissue factor and tissue factor pathway inhibitor in blood coagulation and in thrombotic complications. Kardiol. Pol. 2010; 68:1158–1162. - PubMed
-
- Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 2003;197(11):1585–1598. doi: 10.1084/jem.20021868 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous